Linear, Peptidase-Resistant β2/β3-Di- and α/β3-Tetrapeptide Derivatives with Nanomolar Affinities to a Human Somatostatin Receptor, Preliminary Communication
N‐Acyl‐β2/β3‐dipeptide‐amide somatostatin analogs, 5 – 8, with β2‐HTrp‐β3‐HLys ('natural' sequence) and β2‐HLys‐β3‐HTrp (retro‐sequence) have been synthesized (in solution). Depending on their relative configurations and on the nature of the terminal N‐acyl and terminal C‐amino group, the...
Saved in:
Published in | Helvetica chimica acta Vol. 84; no. 11; pp. 3503 - 3510 |
---|---|
Main Authors | , , , , , , , |
Format | Journal Article |
Language | English |
Published |
Basel
Verlag Helvetica Chimica Acta
14.11.2001
|
Online Access | Get full text |
Cover
Loading…
Summary: | N‐Acyl‐β2/β3‐dipeptide‐amide somatostatin analogs, 5 – 8, with β2‐HTrp‐β3‐HLys ('natural' sequence) and β2‐HLys‐β3‐HTrp (retro‐sequence) have been synthesized (in solution). Depending on their relative configurations and on the nature of the terminal N‐acyl and terminal C‐amino group, the linear β‐dipeptide derivatives have affinities for the human receptor hsst 4, ranging from 250 to >10000 nanomolar (Fig. 3). Also, N‐Ac‐tetrapeptide amides 9 and 10, which contain one α‐ and three β‐amino acid residues (N‐β‐α‐β‐β‐C), have been prepared (solid‐phase synthesis), with the natural (Phe, Trp, Lys, Thr) and the retro‐sequence (Thr, Lys, Trp, Phe) of side chains and with two different configurations, each, of the two central amino acid residues. The novel ‘mixed', linear α/β‐peptides have affinities for the hsst 4 receptor ranging from 23 to >10000 nanomolar (Fig. 4), and, like ‘pure' β‐peptides, they are completely stable to a series of proteolytic enzymes. Thus, the peptidic turn of the cyclic tetradecapeptide somatostatin (Fig. 1) can be mimicked by simple linear di‐ and tetrapeptides. The tendency of β‐dipeptides for forming hydrogen‐bonded rings is confirmed by calculations at the B3LYP/6‐31G(d,p) level (Fig. 2). The reported results open new avenues for the design of low‐molecular‐weight peptidic drugs. |
---|---|
Bibliography: | ark:/67375/WNG-WH5BJP5B-1 istex:2045F5C071E36A3C0A71310B3603433996551924 ArticleID:HLCA3503 ETH‐Zürich. T. K. Part of the projected Ph. D. theses of and Postdoctoral fellow at ETH‐Zürich (2000/2001), financed by the STINT ( M. R. Swedish Foundation for International Cooperation in Research and Higher Education . |
ISSN: | 0018-019X 1522-2675 |
DOI: | 10.1002/1522-2675(20011114)84:11<3503::AID-HLCA3503>3.0.CO;2-A |